Dr. Falk PharmaFalk Foundation
  • About us
    About us
    • Now into the future
    • Innovation drives everything
    • Why we are
    • Corporate Sustainability
    • Following the footsteps of our founder
    • Global presence & business partners
  • Indications
    Indications
    • Autoimmune Hepatitis
    • Chronic Constipation
    • Colonoscopy
    • Crohn’s Disease
    • Eosinophilic Esophagitis
    • Hemorrhoidal disease
    • Irritable Bowel Syndrome
    • Microscopic Colitis
    • Primary Biliary Cholangitis
    • Ulcerative colitis
  • Our Products
  • Partnering
  • Newsroom
Search
Please choose your country
  • Global (English)
  • Australia
  • België (Vlaams)
  • Belgique (Français)
  • Deutschland
  • España
  • France
  • Ireland
  • Italia
  • Luxembourg (Français)
  • Nederland
  • Österreich
  • Portugal
  • Россия
  • Schweiz (Deutsch)
  • Suisse (Français)
  • United Kingdom
more info

Contact:
Phone:+49 0761 1514 0 Fax:+49 0761 1514 321 Email: zentrale@drfalkpharma.de

  • Falk Foundation
  • Contact us
  • Events
  • Reporting adverse events
  • Falsified medicines regulations
  • Imprint
  • Data Privacy
  • Social media guidelines
  • About us
    • Now into the future
    • Innovation drives everything
    • Why we are
    • Corporate Sustainability
    • Following the footsteps of our founder
    • Global presence & business partners
  • Indications
    • Autoimmune Hepatitis
    • Chronic Constipation
    • Colonoscopy
    • Crohn’s Disease
    • Eosinophilic Esophagitis
    • Hemorrhoidal disease
    • Irritable Bowel Syndrome
    • Microscopic Colitis
    • Primary Biliary Cholangitis
    • Ulcerative colitis
  • Our Products
  • Partnering
  • Newsroom
  • Falk Foundation
  • Contact us
  • Events
  • Reporting adverse events
  • Falsified medicines regulations
  • Imprint
  • Data Privacy
  • Social media guidelines
Contact:
Phone:
+49 0761 1514 0
Fax:
+49 0761 1514 321
Email:
zentrale[at]drfalkpharma.de
  • Homepage
  • Search

Search results

109 results

  • NEWSROOM
    Elena in "Australia"
    ... or better in Madrid - for more stories about Falk.
  • NEWSROOM
    Elena in the UK
    ... following her grandpa's footsteps in Edinburgh and London
  • NEWSROOM
    Elena in Germany
    ...the final chapter of her journey following the footsteps of our founder.
  • NEWSROOM
    EASL 2025
    Test
  • Reporting adverse events
    Adverse events Homepage Reporting adverse events Reporting adverse events Reports of suspected side effects relating to our medicinal products can be addressed to pharmakovigilanz@drfalkpharma.de .
  • Events
    Events Homepage Events
  • NEWSROOM
    Advancing the development of naronapride...
    ...for patients with PPI-non-responsive symptomatic GERD as the second naronapride indication
  • «
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • »
Falk Foundation

Discover the range of continuing education opportunities for physicians and pharmacists provided by the Falk Foundation e.V.

Dr. Falk Pharma GmbH

Dr. Falk Pharma is the expert in digestive and metabolic medicine. As a research-based family business with global presence, we focus on the development and distribution of innovative medicines that improve patients’ health and well-being. 

  • Falk Foundation
  • Events
  • Headquarters
  • Reporting adverse events
  • Falsified medicines regulations
  • Social media guidelines
© 2025 Dr. Falk Pharma GmbH
  • Imprint
  • Data Privacy
Notice

This website is an international information resource intended for healthcare professionals outside the United States (US) and United Kingdom (UK).

I am a health care professional outside the US and UK.

Accept
Notice
I confirm I am a UK or Irish resident and have been prescribed either Budenofalk®, Jorveza®, Salofalk® or Ursofalk®
Accept

You are leaving the website of Dr. Falk Pharma.

We are not liable for the accuracy of any content published on third party websites - such as the one you are about to be forwarded to.